Dedicated rare disease unit to be headquartered in Boston
Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care
Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio
Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend
The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities
December 12, 2020 07:48 AM Eastern Standard Time – CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Alexion sale will go down as one of the biggest buyouts in Boston history
Local leaders look on the bright side: AstraZenecaâs decision to base its rare-disease business here
By Jon Chesto Globe Staff,Updated December 14, 2020, 7:54 p.m.
Email to a Friend
Reflections are seen on a sign outside the global headquarters of AstraZeneca in London. England-based pharmaceutical company AstraZeneca, which is involved in development of a COVID-19 vaccine, said during the weekend it is acquiring Boston-based drug developer Alexion Pharmaceuticals in a deal worth $39 billion.Kirsty Wigglesworth/Associated Press/File 2009
Alexion Pharmaceuticals became one of the biggest public companies in Massachusetts overnight by moving its headquarters to Boston less than three years ago.
AstraZenaca to Buy Rare Disease Specialist Alexion for $39 billion
AstraZeneca snaps up Alexion to expand in immunology. PUBLISHED BY
AstraZeneca has struck a deal to buy US rare disease specialist Alexion in a $39 billion cash-and-stock agreement.
The Anglo-Swedish company has undergone quite a transformation in its fortunes after the successful announcement of its coronavirus vaccine with Oxford University. Just six years ago it was on the brink of being swallowed up by Pfizer. The company’s chief executive officer Pascal Soriot worked hard to revitalize his company’s research and development operation, but it failed to make any big strides in new drugs till its foray into cancer drugs and its recent vaccine success.
AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets
AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader by announcing plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020.[Alexion Pharmaceuticals]
December 14, 2020
AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader by announcing plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020.[Alexion Pharmaceuticals]
Share
AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader on Saturday when it announced plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020.
AstraZeneca $39B Acquisition of US biotech Alexion Is Well-Thought Move
Dec 14 2020 · 12:57 UTC by Bhushan Akolkar · 3 min read
Photo; AstraZeneca / Twitter
You have successfully joined our subscriber list.
As part of the massive $39 billion deal, AstraZeneca has agreed to pay a whopping 45% of the share price of Alexion. As per analysts, this could be a win-win situation for both companies.
British pharmaceutical giant AstraZeneca Plc (LON: AZN) has announced one of its largest acquisitions in history. Last Saturday, December 12, the British drugmaker announced its acquisition of US biotech Alexion Pharmaceuticals. The deal closed for a massive $39 billion all in cash and stock.